Mallinckrodt recognized as industry innovator at national organization for rare disorders (nord) 2023 rare impact awards

– terlivaz ® (terlipressin) is the only fda approved treatment for adults with hrs with rapid reduction in kidney function1 – dublin , may 5, 2023 /prnewswire/ -- mallinckrodt plc (nyse american: mnk), a global specialty pharmaceutical company, is pleased to announce it has received an award from the national organization for rare disorders (nord), recognizing it as an "industry innovator" for the creation of a treatment "to improve the lives of rare disease patients." mallinckrodt is being recognized for the u.s. food and drug administration (fda) approval of terlivaz ® (terlipressin) for injection for the treatment of adults with hrs with rapid reduction in kidney function.1  terlivaz, the first and only fda-approved product indicated for the treatment of adults with hepatorenal syndrome (hrs) involving rapid reduction in kidney function,1 an acute and life-threatening condition requiring hospitalization,2 was approved for use on september 14, 2022.
MNK Ratings Summary
MNK Quant Ranking